nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—OPRL1—nervous system—Gilles de la Tourette syndrome	0.072	0.114	CbGeAlD
Buprenorphine—OPRL1—central nervous system—Gilles de la Tourette syndrome	0.0693	0.11	CbGeAlD
Buprenorphine—OPRL1—brain—Gilles de la Tourette syndrome	0.055	0.087	CbGeAlD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0438	0.119	CbGpPWpGaD
Buprenorphine—OPRD1—nervous system—Gilles de la Tourette syndrome	0.0371	0.0586	CbGeAlD
Buprenorphine—OPRD1—central nervous system—Gilles de la Tourette syndrome	0.0357	0.0564	CbGeAlD
Buprenorphine—OPRK1—nervous system—Gilles de la Tourette syndrome	0.0356	0.0562	CbGeAlD
Buprenorphine—OPRK1—central nervous system—Gilles de la Tourette syndrome	0.0342	0.0541	CbGeAlD
Buprenorphine—OPRM1—midbrain—Gilles de la Tourette syndrome	0.0308	0.0486	CbGeAlD
Buprenorphine—OPRD1—brain—Gilles de la Tourette syndrome	0.0283	0.0448	CbGeAlD
Buprenorphine—OPRK1—brain—Gilles de la Tourette syndrome	0.0272	0.043	CbGeAlD
Buprenorphine—OPRM1—nervous system—Gilles de la Tourette syndrome	0.0253	0.04	CbGeAlD
Buprenorphine—OPRM1—central nervous system—Gilles de la Tourette syndrome	0.0243	0.0385	CbGeAlD
Buprenorphine—CYP2A6—brain—Gilles de la Tourette syndrome	0.0207	0.0327	CbGeAlD
Buprenorphine—OPRM1—brain—Gilles de la Tourette syndrome	0.0193	0.0306	CbGeAlD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0187	0.0509	CbGpPWpGaD
Buprenorphine—ABCG2—midbrain—Gilles de la Tourette syndrome	0.018	0.0284	CbGeAlD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0164	0.0446	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0139	0.0377	CbGpPWpGaD
Buprenorphine—CYP2C8—brain—Gilles de la Tourette syndrome	0.0116	0.0184	CbGeAlD
Buprenorphine—ABCG2—brain—Gilles de la Tourette syndrome	0.0113	0.0179	CbGeAlD
Buprenorphine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.0103	0.0163	CbGeAlD
Buprenorphine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.0101	0.016	CbGeAlD
Buprenorphine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00992	0.0157	CbGeAlD
Buprenorphine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00976	0.0154	CbGeAlD
Buprenorphine—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00887	0.014	CbGeAlD
Buprenorphine—OPRL1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.0088	0.0239	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00854	0.0232	CbGpPWpGaD
Buprenorphine—OPRL1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00796	0.0217	CbGpPWpGaD
Buprenorphine—OPRL1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00777	0.0211	CbGpPWpGaD
Buprenorphine—CYP2D6—brain—Gilles de la Tourette syndrome	0.00775	0.0123	CbGeAlD
Buprenorphine—OPRL1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00754	0.0205	CbGpPWpGaD
Buprenorphine—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00729	0.0115	CbGeAlD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00721	0.0196	CbGpPWpGaD
Buprenorphine—OPRL1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00702	0.0191	CbGpPWpGaD
Buprenorphine—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.00702	0.0111	CbGeAlD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.007	0.019	CbGpPWpGaD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00652	0.0177	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00618	0.0168	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00599	0.0163	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00558	0.0152	CbGpPWpGaD
Buprenorphine—ABCB1—brain—Gilles de la Tourette syndrome	0.00557	0.00881	CbGeAlD
Buprenorphine—OPRL1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0047	0.0128	CbGpPWpGaD
Buprenorphine—OPRL1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00457	0.0124	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00457	0.0124	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00425	0.0116	CbGpPWpGaD
Buprenorphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00391	0.0106	CbGpPWpGaD
Buprenorphine—UGT1A9—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.00338	0.00921	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00332	0.00902	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00322	0.00876	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00308	0.00837	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.003	0.00816	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00299	0.00813	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00298	0.0081	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00291	0.00791	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00282	0.00768	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00278	0.00757	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0027	0.00734	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00266	0.00723	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00264	0.00717	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00263	0.00715	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00262	0.00713	CbGpPWpGaD
Buprenorphine—CYP2A6—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.00261	0.0071	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00258	0.00702	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00256	0.00696	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00246	0.00669	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00244	0.00664	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00241	0.00657	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0024	0.00654	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00239	0.00649	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00238	0.00649	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00234	0.00637	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00231	0.00629	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00228	0.0062	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00224	0.00611	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00222	0.00605	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00221	0.00602	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00218	0.00594	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00209	0.00569	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00206	0.00561	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00201	0.00546	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00195	0.00532	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00195	0.0053	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00195	0.0053	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0019	0.00516	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—HDC—Gilles de la Tourette syndrome	0.00185	0.00502	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00182	0.00494	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00177	0.00481	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00176	0.00479	CbGpPWpGaD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00171	0.00465	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00171	0.00465	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00168	0.00458	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00167	0.00454	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00159	0.00433	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00153	0.00416	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00149	0.00405	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00146	0.00398	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—HDC—Gilles de la Tourette syndrome	0.00146	0.00397	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00144	0.00393	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00144	0.00393	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00143	0.00388	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00138	0.00377	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00135	0.00366	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00129	0.00351	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00127	0.00346	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00124	0.00337	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00124	0.00337	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—HDC—Gilles de la Tourette syndrome	0.00123	0.00334	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00113	0.00309	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00112	0.00306	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00111	0.00303	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.0011	0.003	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00103	0.0028	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00103	0.00279	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.001	0.00272	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000995	0.00271	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000966	0.00263	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000942	0.00256	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000932	0.00253	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00092	0.0025	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000903	0.00246	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000903	0.00246	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0009	0.00245	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	0.000887	0.00241	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000877	0.00239	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000841	0.00229	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000817	0.00222	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000816	0.00222	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	0.000768	0.00209	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000763	0.00208	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00076	0.00207	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000741	0.00202	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000719	0.00196	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00069	0.00188	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	0.000686	0.00187	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000669	0.00182	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000652	0.00178	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000631	0.00172	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00063	0.00171	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000625	0.0017	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000609	0.00166	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000591	0.00161	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000572	0.00156	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00055	0.0015	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000534	0.00145	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000534	0.00145	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000532	0.00145	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000518	0.00141	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000497	0.00135	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000484	0.00132	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000483	0.00131	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000451	0.00123	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000438	0.00119	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000412	0.00112	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000408	0.00111	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000385	0.00105	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000338	0.00092	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000286	0.000777	CbGpPWpGaD
